Entering text into the input field will update the search result below

Bristol Myers' Opdivo/Yervoy combo fails to improve overall survival in certain bladder cancer patients in trial

May 16, 2022 8:01 AM ETBristol-Myers Squibb Company (BMY) StockBy: Ravikash Bakolia, SA News Editor

Stock Markets Open One Day After Steep Drop Over Apple"s Revised Forecast

Drew Angerer/Getty Images News

Bristol Myers Squibb's (NYSE:BMY) late-stage study of Opdivo plus Yervoy as a first-line therapy, did not meet the main goal of overall survival (OS) in certain patients with bladder cancer.

The phase 3 trial called CheckMate -901

Recommended For You

More Trending News

About BMY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BMY--
Bristol-Myers Squibb Company